Rockville, Md.-based Human Genome Sciences on Monday acquired exclusive rights to an antibody that could be used to slow HIV replication in the bodies of HIV-positive people, The Baltimore Sun reports. Under a licensing deal with Angenix, a California pharmaceutical company, HGS gained exclusive rights to the CCR5 mAb antibody, which prevents cellular HIV infection by jamming a key receptor on the surface of immune system cells that HIV must latch on to in order to enter the cells. A Phase I clinical trial of the antibody is planned to begin later this year.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














